Literature DB >> 9120273

MHC class I ligation of human T cells activates the ZAP70 and p56lck tyrosine kinases, leads to an alternative phenotype of the TCR/CD3 zeta-chain, and induces apoptosis.

S Skov1, S Bregenholt, M H Claesson.   

Abstract

Cross-linking of MHC class I (MHC-I) molecules on human T cells induces signal-transduction events, including activation of tyrosine kinases, tyrosine phosphorylation of phospholipase C-gamma 1, and elevation of the intracellular free calcium concentration. In this study, we demonstrate that the ZAP70 tyrosine kinase is tyrosine phosphorylated in Jurkat T cells and in purified peripheral T cells after MHC-I ligation. The tyrosine-phosphorylated ZAP70 kinase exhibits a particular phenotype with low affinities for proteins at 21, 40, 60, and 120 kDa, proteins normally co-precipitated with ZAP70 after TCR/CD3 stimulation. The phosphorylation of ZAP70 after MHC-I ligation was dependent on TCR/CD3 surface expression. One of the natural substrates for ZAP70 is the zeta-chain dimer of the TCR/CD3 complex. MHC-I cross-linking induces a phosphorylated zeta-protein that migrates as a dimer at 42 kDa in SDS-PAGE and differs from the 38-kDa phosphorylated zeta-protein dimer induced by TCR/CD3 cross-linking. Furthermore, we demonstrate that the p56lck tyrosine kinase is tyrosine phosphorylated following MHC-I ligation, and that a p56lck-negative Jurkat T cell mutant does not induce phosphorylation of the zeta-chain and the ZAP70 kinase following MHC-I ligation. Previous studies have demonstrated that lack or diminished activation of ZAP70 is involved in the induction of anergy or apoptosis in T cells. Likewise, MHC-I cross-linking of Jurkat T cells results in growth arrest and induction of apoptosis that is strongly inhibited by herbimycin A, suggesting an essential role of tyrosine kinase activity in the process leading to apoptosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120273

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis.

Authors:  B Murphy; C C Magee; S I Alexander; A M Waaga; H W Snoeck; J P Vella; C B Carpenter; M H Sayegh
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

2.  MHCI requires MEF2 transcription factors to negatively regulate synapse density during development and in disease.

Authors:  Bradford M Elmer; Myka L Estes; Stephanie L Barrow; A Kimberley McAllister
Journal:  J Neurosci       Date:  2013-08-21       Impact factor: 6.167

Review 3.  The link between major histocompatibility complex antibodies and cell proliferation.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Transplant Rev (Orlando)       Date:  2011-07-30       Impact factor: 3.943

4.  In vitro activated CD4+ T cells from interferon-gamma (IFN-gamma)-deficient mice induce intestinal inflammation in immunodeficient hosts.

Authors:  S Bregenholt; J Brimnes; M H Nissen; M H Claesson
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

5.  Characterization of signaling function and expression of HLA class I molecules in medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Elisabeth J Rushing; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Neurooncol       Date:  2010-09-02       Impact factor: 4.130

Review 6.  Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules.

Authors:  Jing Yang; Qing Yi
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

7.  Activation-induced T cell death, and aberrant T cell activation via TNFR1 and CD95-CD95 ligand pathway in stable cardiac transplant recipients.

Authors:  H J Ankersmit; B Moser; A Zuckermann; G Roth; S Taghavi; M Brunner; E Wolner; G Boltz-Nitulescu
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

8.  Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.

Authors:  Jing Yang; Yabing Cao; Sungyongl Hong; Haiyan Li; Jianfei Qian; Larry W Kwak; Qing Yi
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

9.  A novel role of HLA class I in the pathology of medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Bhargavi Rajan; Elisabeth J Rushing; Mi Rim Choi; Brian R Rood; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Transl Med       Date:  2009-07-12       Impact factor: 5.531

10.  HLA class I binding 9mer peptides from influenza A virus induce CD4 T cell responses.

Authors:  Mingjun Wang; Mette V Larsen; Morten Nielsen; Mikkel Harndahl; Sune Justesen; Morten H Dziegiel; Søren Buus; Sheila T Tang; Ole Lund; Mogens H Claesson
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.